Team Veye May 29, 2026

Acrux Further Updates on $5.4m Australian Lenzetto Licensing Deal

Get your Free Report on Top 5 ASX stocks for 2025

Acrux Limited, today, provided more details on the milestone structure regarding its recently announced licensing agreement for menopause therapy Lenzetto® in Australia, which could deliver up to AUD 5.4 million in payments to the company.

The company reported that the initial payment under the agreement with its long-time partner Gedeon Richter Plc will be an upfront signing milestone. This would become payable within 14 days of executing the amended licensing agreement.

A second milestone payment will become due once Lenzetto® receives marketing authorisation from Australia’s Therapeutic Goods Administration (TGA).

The final commercial milestone payment will be activated either upon achieving of cumulative sales targets or on the second anniversary of the product’s launch, whichever happens first.

The update follows Acrux’s announcement yesterday that it had expanded its licensing agreement with Richter to launch Lenzetto® in the Australian market. The product is expected to give relief to ongoing shortages of Menopause Hormone Therapy (MHT) treatments.

Lenzetto®, a transdermal Estradiol spray is developed by Acrux, and already marketed in more than 40 countries worldwide as a hormone replacement therapy for symptoms associated with menopause, including hot flushes.

(Source: Company Reports)

Disclaimer

Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.

Name

Email address

Phone

By providing your details, you agree to Veye’s Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers by email, text message or phone call from us or our agents until you opt out. Before you access our services, please read the Financial Service Guide available here.